Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Proc Natl Acad Sci U S A ; 103(21): 8215-20, 2006 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-16698938

RESUMEN

Deposition of plaques containing amyloid beta (Abeta) peptides is a neuropathological hallmark of Alzheimer's disease (AD). Here we demonstrate that neuronal overexpression of the epsilon isozyme of PKC decreases Abeta levels, plaque burden, and plaque-associated neuritic dystrophy and reactive astrocytosis in transgenic mice expressing familial AD-mutant forms of the human amyloid precursor protein (APP). Compared with APP singly transgenic mice, APP/PKCepsilon doubly transgenic mice had decreased Abeta levels but showed no evidence for altered cleavage of APP. Instead, PKCepsilon overexpression selectively increased the activity of endothelin-converting enzyme, which degrades Abeta. The activities of other Abeta-degrading enzymes, insulin degrading enzyme and neprilysin, were unchanged. These results indicate that increased neuronal PKCepsilon activity can promote Abeta clearance and reduce AD neuropathology through increased endothelin-converting enzyme activity.


Asunto(s)
Amiloide/química , Ácido Aspártico Endopeptidasas/metabolismo , Metaloendopeptidasas/metabolismo , Proteína Quinasa C-epsilon/fisiología , Animales , Encéfalo/metabolismo , Enzimas Convertidoras de Endotelina , Endotelio Vascular/citología , Gliosis/patología , Hipocampo/metabolismo , Humanos , Ratones , Ratones Transgénicos , Enfermedades Neurodegenerativas/patología , Neuronas/metabolismo , Fosforilación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA